Miller Lawrence G.
CIK: 0001572378
Associated companies
Transaction History
| APMD | ▼ Sell | Other | 92,431 | — | 8/3/2026 | View on chart |
| APMD | ▲ Buy | Grant | 92,431 | — | 8/3/2026 | View on chart |
| APMD | ▼ Sell | Other | 10,845 | — | 8/3/2026 | View on chart |
| APMD | ▲ Buy | Grant | 88,954 | — | 8/3/2026 | View on chart |
| APMD | ▼ Sell | Other | 88,954 | — | 8/3/2026 | View on chart |
| APMD | ▲ Buy | Grant | 88,954 | — | 8/3/2026 | View on chart |
| APMD | ▼ Sell | Other | 88,954 | — | 8/3/2026 | View on chart |
| APMD | ▲ Buy | Grant | 88,954 | — | 8/3/2026 | View on chart |
| APMD | ▼ Sell | Other | 88,954 | — | 8/3/2026 | View on chart |
| APMD | ▲ Buy | Grant | 88,954 | — | 8/3/2026 | View on chart |
| APMD | ▼ Sell | Other | 88,954 | — | 8/3/2026 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 15, 2026
Apnimed to Present Five Abstracts at CHEST 2026
Apnimed announced it will present five abstracts, including two late-breaking studies, at the CHEST 2026 conference. This highlights the company's ongoing research activity and clinical data generation. The stock currently trades well below its 52-week high, with an average analyst target of $50.33.
Apnimed to Present Five Abstracts at CHEST 2026. Apnimed announced it will present five abstracts, including two late-breaking studies, at the CHEST 2026 conference. This highlights the company's ongoing research activity and clinical data generation. The stock currently trades well below its 52-week high, with an average analyst target of $50.33.